表紙:世界と日本のT細胞・NK細胞結合型二重特異性抗体市場:分析・予測 (2028年まで)
市場調査レポート
商品コード
1073207

世界と日本のT細胞・NK細胞結合型二重特異性抗体市場:分析・予測 (2028年まで)

Global and Japan T-Cell & NK-Cell Engaging Bispecific Antibodies Market Insights, Forecast to 2028

出版日: | 発行: QYResearch | ページ情報: 英文 110 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=128.51円
世界と日本のT細胞・NK細胞結合型二重特異性抗体市場:分析・予測 (2028年まで)
出版日: 2022年05月07日
発行: QYResearch
ページ情報: 英文 110 Pages
納期: 2~3営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のT細胞・NK細胞結合型二重特異性抗体の市場規模は、2021年に4億7,200万米ドル、2028年末までに50億7,200万米ドルに達すると予測されています。

また、2021年から2028年の間に40.82%のCAGRで成長する見通しです。一方、日本のT細胞・NK細胞結合型二重特異性抗体の市場規模は、2021年には188万米ドル、2028年までに1億7,315万米ドルと、予測期間中に99.82%のCAGRで成長すると予測されています。

当レポートでは、世界と韓国のT細胞・NK細胞結合型二重特異性抗体の市場について分析し、種類別・用途別・地域別 (国別) の市場動向の見通し (2017年~2028年)、主要企業のプロファイルなどについて調査しております。

目次

第1章 調査概要

  • 調査範囲
  • 種類別の市場分析
    • 市場規模・成長率:種類別 (2017年・2021年・2028年)
    • T細胞結合型
    • NK細胞 (ナチュラルキラー細胞) 結合型
  • 用途別の市場
    • 市場シェア:用途別 (2017年・2021年・2028年)
    • 血液がん
    • 固形腫瘍
  • 分析対象
  • 分析期間

第2章 世界の成長動向

  • 世界のT細胞・NK細胞結合型二重特異性抗体市場の展望 (2017年~2028年)
  • T細胞・NK細胞結合型二重特異性抗体の成長動向:地域別
  • T細胞・NK細胞結合型二重特異性抗体業界の力学

第3章 主要企業別の競合情勢

  • 主要T細胞・NK細胞結合型二重特異性抗体企業の収益
  • 市場シェア:企業の種類別 (ティア1、ティア2、ティア3)
  • 分析対象企業:T細胞・NK細胞結合型二重特異性抗体の収益別のランキング
  • 世界のT細胞・NK細胞結合型二重特異性抗体市場の集中度
  • T細胞・NK細胞結合型二重特異性抗体の主要企業:本社・提供エリア
  • T細胞・NK細胞結合型二重特異性抗体の主要企業:製品・ソリューション・サービス
  • T細胞・NK細胞結合型二重特異性抗体市場への参入時期
  • 企業合併・買収 (M&A)、拡張計画

第4章 T細胞・NK細胞結合型二重特異性抗体:種類別の内訳データ

  • 過去の市場規模:種類別 (2017年~2022年)
  • 市場規模の予測:種類別 (2023年~2028年)

第5章 T細胞・NK細胞結合型二重特異性抗体:用途別の内訳データ

  • 過去の市場規模:用途別 (2017年~2022年)
  • 市場規模の予測:用途別 (2023年~2028年)

第6章 北米

  • 北米のT細胞・NK細胞結合型二重特異性抗体の市場規模 (2017年~2028年)
  • T細胞・NK細胞結合型二重特異性抗体の市場規模:種類別 (2017年~2022年)
  • T細胞・NK細胞結合型二重特異性抗体の市場規模:用途別 (2017年~2022年)
  • T細胞・NK細胞結合型二重特異性抗体の市場規模:国別 (2017年~2022年)
    • 米国
    • カナダ
    • メキシコ

第7章 欧州

  • 欧州のT細胞・NK細胞結合型二重特異性抗体の市場規模 (2017年~2028年)
  • T細胞・NK細胞結合型二重特異性抗体の市場規模:種類別 (2017年~2022年)
  • T細胞・NK細胞結合型二重特異性抗体の市場規模:用途別 (2017年~2022年)
  • T細胞・NK細胞結合型二重特異性抗体の市場規模:国別 (2017年~2022年)
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • ロシア

第8章 アジア太平洋

  • アジア太平洋のT細胞・NK細胞結合型二重特異性抗体の市場規模 (2017年~2028年)
  • T細胞・NK細胞結合型二重特異性抗体の市場規模:種類別 (2017年~2022年)
  • T細胞・NK細胞結合型二重特異性抗体の市場規模:用途別 (2017年~2022年)
  • T細胞・NK細胞結合型二重特異性抗体の市場規模:地域別 (2017年~2022年)
    • 中国
    • 日本
    • 韓国
    • 東南アジア
    • インド

第9章 南米

  • 南米のT細胞・NK細胞結合型二重特異性抗体の市場規模 (2017年~2028年)
  • T細胞・NK細胞結合型二重特異性抗体の市場規模:種類別 (2017年~2022年)
  • T細胞・NK細胞結合型二重特異性抗体の市場規模:用途別 (2017年~2022年)
  • T細胞・NK細胞結合型二重特異性抗体の市場規模:国別 (2017年~2022年)
    • ブラジル

第10章 中東・アフリカ

  • 中東・アフリカのT細胞・NK細胞結合型二重特異性抗体の市場規模 (2017年~2028年)
  • T細胞・NK細胞結合型二重特異性抗体の市場規模:種類別 (2017年~2022年)
  • T細胞・NK細胞結合型二重特異性抗体の市場規模:用途別 (2017年~2022年)
  • T細胞・NK細胞結合型二重特異性抗体の市場規模:国別 (2017年~2022年)
    • 中東
    • アフリカ

第11章 主要企業のプロファイル

  • Amgen
  • Immunocore
  • Johnson &Johnson
  • Roche
  • Pfizer
  • AbbVie
  • MacroGenics
  • Regeneron
  • Astellas Pharma
  • GEMoaB Monoclonals
  • Molecular Partners
  • AstraZeneca
  • Merck
  • Eli Lilly
  • IGM Biosciences
  • Novartis
  • CytomX Therapeutics
  • Lava Therapeutics
  • Takeda

第12章 アナリストの見解/結論

第13章 付録

図表

LIST OF TABLES

  • Table 1. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
  • Table 2. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
  • Table 3. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Regions (US$ Million): 2017 VS 2021 VS 2028
  • Table 4. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Regions (2017-2022) & (US$ Million)
  • Table 5. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Regions (2017-2022)
  • Table 6. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Forecasted Market Size by Regions (2023-2028) & (US$ Million)
  • Table 7. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Regions (2023-2028)
  • Table 8. T-Cell & NK-Cell Engaging Bispecific Antibodies Market Trends
  • Table 9. T-Cell & NK-Cell Engaging Bispecific Antibodies Market Drivers
  • Table 10. T-Cell & NK-Cell Engaging Bispecific Antibodies Market Challenges
  • Table 11. T-Cell & NK-Cell Engaging Bispecific Antibodies Market Restraints
  • Table 12. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue by Players (2017-2022) & (US$ Million)
  • Table 13. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Players (2017-2022)
  • Table 14. Global Top T-Cell & NK-Cell Engaging Bispecific Antibodies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in T-Cell & NK-Cell Engaging Bispecific Antibodies as of 2022)
  • Table 15. Ranking of Global Top T-Cell & NK-Cell Engaging Bispecific Antibodies Companies by Revenue (US$ Million) in 2021
  • Table 16. Global 5 Largest Players Market Share by T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue (CR5 and HHI) & (2017-2022)
  • Table 17. Key Players Headquarters and Area Served
  • Table 18. Key Players T-Cell & NK-Cell Engaging Bispecific Antibodies Product Solution and Service
  • Table 19. Date of Enter into T-Cell & NK-Cell Engaging Bispecific Antibodies Market
  • Table 20. Mergers & Acquisitions, Expansion Plans
  • Table 21. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Type (2017-2022) & (US$ Million)
  • Table 22. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Type (2017-2022)
  • Table 23. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Forecasted Market Size by Type (2023-2028) & (US$ Million)
  • Table 24. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Type (2023-2028)
  • Table 25. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Application (2017-2022) & (US$ Million)
  • Table 26. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Application (2017-2022)
  • Table 27. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Forecasted Market Size by Application (2023-2028) & (US$ Million)
  • Table 28. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Application (2023-2028)
  • Table 29. North America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Type (2017-2022) & (US$ Million)
  • Table 30. North America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Type (2017-2022)
  • Table 31. North America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Application (2017-2022) & (US$ Million)
  • Table 32. North America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Application (2017-2022)
  • Table 33. North America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Country (2017-2022) & (US$ Million)
  • Table 34. North America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Country (2017-2022)
  • Table 35. Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Type (2017-2022) & (US$ Million)
  • Table 36. Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Type (2017-2022)
  • Table 37. Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Application (2017-2022) & (US$ Million)
  • Table 38. Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Application (2017-2022)
  • Table 39. Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Country (2017-2022) & (US$ Million)
  • Table 40. Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Country (2017-2022)
  • Table 41. Asia-Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Type (2017-2022) & (US$ Million)
  • Table 42. Asia-Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Type (2017-2022)
  • Table 43. Asia-Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Application (2017-2022) & (US$ Million)
  • Table 44. Asia-Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Application (2017-2022)
  • Table 45. Asia-Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Region (2017-2022) & (US$ Million)
  • Table 46. Asia-Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Region (2017-2022)
  • Table 47. South America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Type (2017-2022) & (US$ Million)
  • Table 48. South America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Type (2017-2022)
  • Table 49. South America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Application (2017-2022) & (US$ Million)
  • Table 50. South America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Application (2017-2022)
  • Table 51. South America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Country (2017-2022) & (US$ Million)
  • Table 52. South America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Country (2017-2022)
  • Table 53. Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Type (2017-2022) & (US$ Million)
  • Table 54. Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Type (2017-2022)
  • Table 55. Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Application (2017-2022) & (US$ Million)
  • Table 56. Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Application (2017-2022)
  • Table 57. Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Country (2017-2022) & (US$ Million)
  • Table 58. Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Country (2017-2022)
  • Table 59. Amgen Company Details
  • Table 60. Amgen Business Overview
  • Table 61. Amgen T-Cell & NK-Cell Engaging Bispecific Antibodies Product
  • Table 62. Amgen Revenue in T-Cell & NK-Cell Engaging Bispecific Antibodies Business (2017-2022) & (US$ Million)
  • Table 63. Amgen Recent Development
  • Table 64. Immunocore Company Details
  • Table 65. Immunocore Business Overview
  • Table 66. Immunocore T-Cell & NK-Cell Engaging Bispecific Antibodies Product
  • Table 67. Immunocore Revenue in T-Cell & NK-Cell Engaging Bispecific Antibodies Business (2017-2022) & (US$ Million)
  • Table 68. Immunocore Recent Development
  • Table 69. Johnson & Johnson Company Details
  • Table 70. Johnson & Johnson Business Overview
  • Table 71. Johnson & Johnson T-Cell & NK-Cell Engaging Bispecific Antibodies Product
  • Table 72. Johnson & Johnson Recent Development
  • Table 73. Roche Company Details
  • Table 74. Roche Business Overview
  • Table 75. Roche T-Cell & NK-Cell Engaging Bispecific Antibodies Product
  • Table 76. Roche Recent Development
  • Table 77. Pfizer Company Details
  • Table 78. Pfizer Business Overview
  • Table 79. Pfizer T-Cell & NK-Cell Engaging Bispecific Antibodies Product
  • Table 80. Pfizer Recent Development
  • Table 81. AbbVie Company Details
  • Table 82. AbbVie Business Overview
  • Table 83. AbbVie T-Cell & NK-Cell Engaging Bispecific Antibodies Product
  • Table 84. AbbVie Recent Development
  • Table 85. MacroGenics Company Details
  • Table 86. MacroGenics Business Overview
  • Table 87. MacroGenics T-Cell & NK-Cell Engaging Bispecific Antibodies Product
  • Table 88. MacroGenics Recent Development
  • Table 89. Regeneron Company Details
  • Table 90. Regeneron Business Overview
  • Table 91. Regeneron T-Cell & NK-Cell Engaging Bispecific Antibodies Product
  • Table 92. Regeneron Recent Development
  • Table 93. Astellas Pharma Company Details
  • Table 94. Astellas Pharma Business Overview
  • Table 95. Astellas Pharma Recent Development
  • Table 96. GEMoaB Monoclonals Company Details
  • Table 97. GEMoaB Monoclonals Business Overview
  • Table 98. GEMoaB Monoclonals Recent Development
  • Table 99. Molecular Partners Company Details
  • Table 100. Molecular Partners Business Overview
  • Table 101. Molecular Partners Recent Development
  • Table 102. AstraZeneca Company Details
  • Table 103. AstraZeneca Business Overview
  • Table 104. AstraZeneca Recent Development
  • Table 105. Merck Company Details
  • Table 106. Merck Business Overview
  • Table 107. Merck Recent Development
  • Table 108. Eli Lilly Company Details
  • Table 109. Eli Lilly Business Overview
  • Table 110. Eli Lilly Recent Development
  • Table 111. IGM Biosciences Company Details
  • Table 112. IGM Biosciences Business Overview
  • Table 113. IGM Biosciences Recent Development
  • Table 114. Novartis Company Details
  • Table 115. Novartis Business Overview
  • Table 116. Novartis Recent Development
  • Table 117. CytomX Therapeutics Company Details
  • Table 118. CytomX Therapeutics Business Overview
  • Table 119. CytomX Therapeutics Recent Development
  • Table 120. Lava Therapeutics Company Details
  • Table 121. Lava Therapeutics Business Overview
  • Table 122. Lava Therapeutics Recent Development
  • Table 123. Takeda Company Details
  • Table 124. Takeda Business Overview
  • Table 125. Takeda Recent Development
  • Table 126. Research Programs/Design for This Report
  • Table 127. Key Data Information from Secondary Sources
  • Table 128. Key Data Information from Primary Sources

List of Figures

  • Figure 1. T-Cell & NK-Cell Engaging Bispecific Antibodies Product Picture
  • Figure 2. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Type: 2021
  • Figure 3. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Type: 2028
  • Figure 4. T Cell Engagers Features
  • Figure 5. NK Cell Engagers Features
  • Figure 6. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Application: 2021
  • Figure 7. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Application: 2028
  • Figure 8. T-Cell & NK-Cell Engaging Bispecific Antibodies Report Years Considered
  • Figure 9. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size (US$ Million), Year-over-Year: 2017-2028
  • Figure 10. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size, (US$ Million), 2017 VS 2022 VS 2028
  • Figure 11. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Regions: 2021
  • Figure 12. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Regions: 2028
  • Figure 13. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Regions (2017-2028)
  • Figure 14. Japan T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share in Global Market 2017-2028
  • Figure 15. Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Players in 2021
  • Figure 16. The Top 2 Players Market Share by T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue in 2021
  • Figure 17. North America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 18. United States T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 19. Canada T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 20. Mexico T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 21. Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 22. Germany T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 23. France T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 24. U.K. T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 25. Italy T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 26. Russia T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 27. Asia-Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 28. China T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 29. Japan T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 30. South Korea T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 31. Southeast Asia T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 32. India T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 33. South America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 34. Brazil T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 35. Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 36. Middle East T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 37. Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 38. Bottom-up and Top-down Approaches for This Report
  • Figure 39. Data Triangulation
  • Figure 40. Key Executives Interviewed
目次

Market Analysis and Insights:

This report focuses on global and Japan T-Cell & NK-Cell Engaging Bispecific Antibodies market.

In 2021, the global T-Cell & NK-Cell Engaging Bispecific Antibodies market size was US$ 472 million and it is expected to reach US$ 5072 million by the end of 2028, with a CAGR of 40.82% during 2021-2028. In Japan the T-Cell & NK-Cell Engaging Bispecific Antibodies market size is expected to grow from US$ 1.88 million in 2021 to US$ 173.15 million by 2028, at a CAGR of 99.82% during the forecast period.

Scope and Market Size:

T-Cell & NK-Cell Engaging Bispecific Antibodies market is segmented by players, region (country), by Type, and By Application. Players, stakeholders, and other participants in the global T-Cell & NK-Cell Engaging Bispecific Antibodies market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and By Application in terms of revenue and forecast for the period 2017-2028.

By Company

  • Amgen
  • Immunocore
  • Johnson & Johnson
  • Roche
  • Company Five
  • AbbVie
  • MacroGenics
  • Regeneron
  • Astellas Pharma
  • GEMoaB Monoclonals
  • Molecular Partners
  • AstraZeneca
  • Merck
  • Eli Lilly
  • IGM Biosciences
  • Novartis
  • CytomX Therapeutics
  • Lava Therapeutics
  • Takeda

Segment by Type

  • T Cell Engagers
  • NK Cell Engagers

Segment by Application

  • Hematological Cancers
  • Solid Tumors

By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • Australia
    • India
    • Rest of Asia
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Russia
    • Rest of Europe
  • South America
    • Brazil
    • Rest of South America
  • Middle East & Africa
    • Middle East
    • Africa

TABLE OF CONTENTS

1 REPORT OVERVIEW

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
    • 1.2.2 T Cell Engagers
    • 1.2.3 NK Cell Engagers
  • 1.3 Market by Application
    • 1.3.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share by Application: 2017 VS 2021 VS 2028
    • 1.3.2 Hematological Cancers
    • 1.3.3 Solid Tumors
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 GLOBAL GROWTH TRENDS

  • 2.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Perspective (2017-2028)
  • 2.2 T-Cell & NK-Cell Engaging Bispecific Antibodies Growth Trends by Regions
    • 2.2.1 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Regions: 2017 VS 2021 VS 2028
    • 2.2.2 T-Cell & NK-Cell Engaging Bispecific Antibodies Historic Market Size by Regions (2017-2022)
    • 2.2.3 T-Cell & NK-Cell Engaging Bispecific Antibodies Forecasted Market Size by Regions (2023-2028)
    • 2.2.4 Japan T-Cell & NK-Cell Engaging Bispecific Antibodies Market Share in Global Market 2017-2028
  • 2.3 T-Cell & NK-Cell Engaging Bispecific Antibodies Industry Dynamic
    • 2.3.1 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Trends
    • 2.3.2 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Drivers
    • 2.3.3 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Challenges
    • 2.3.4 T-Cell & NK-Cell Engaging Bispecific Antibodies Market Restraints

3 COMPETITION LANDSCAPE BY KEY PLAYERS

  • 3.1 Global Top T-Cell & NK-Cell Engaging Bispecific Antibodies Players by Revenue
    • 3.1.1 Global Top T-Cell & NK-Cell Engaging Bispecific Antibodies Players by Revenue (2017-2022)
    • 3.1.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue Market Share by Players (2017-2022)
  • 3.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies by Company Type (Tier 1, Tier 2, and Tier 3)
  • 3.3 Players Covered: Ranking by T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue
  • 3.4 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Concentration Ratio
    • 3.4.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 2 Companies by T-Cell & NK-Cell Engaging Bispecific Antibodies Revenue in 2021
  • 3.5 T-Cell & NK-Cell Engaging Bispecific Antibodies Key Players Head office and Area Served
  • 3.6 Key Players T-Cell & NK-Cell Engaging Bispecific Antibodies Product Solution and Service
  • 3.7 Date of Enter into T-Cell & NK-Cell Engaging Bispecific Antibodies Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES BREAKDOWN DATA BY TYPE

  • 4.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Historic Market Size by Type (2017-2022)
  • 4.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Forecasted Market Size by Type (2023-2028)

5 T-CELL & NK-CELL ENGAGING BISPECIFIC ANTIBODIES BREAKDOWN DATA BY APPLICATION

  • 5.1 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Historic Market Size by Application (2017-2022)
  • 5.2 Global T-Cell & NK-Cell Engaging Bispecific Antibodies Forecasted Market Size by Application (2023-2028)

6 NORTH AMERICA

  • 6.1 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size (2017-2028)
  • 6.2 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Type (2017-2022)
  • 6.3 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Application (2017-2022)
  • 6.4 North America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Country (2017-2022)
    • 6.4.1 United States
    • 6.4.2 Canada
    • 6.4.3 Mexico

7 EUROPE

  • 7.1 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size (2017-2028)
  • 7.2 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Type (2017-2022)
  • 7.3 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Application (2017-2022)
  • 7.4 Europe T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Country (2017-2022)
    • 7.4.1 Germany
    • 7.4.2 France
    • 7.4.3 U.K.
    • 7.4.4 Italy
    • 7.4.5 Russia

8 ASIA-PACIFIC

  • 8.1 Asia-Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size (2017-2028)
  • 8.2 Asia-Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Type (2017-2022)
  • 8.3 Asia-Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Application (2017-2022)
  • 8.4 Asia-Pacific T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Region (2017-2022)
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 Southeast Asia
    • 8.4.5 India

9 SOUTH AMERICA

  • 9.1 South America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size (2017-2028)
  • 9.2 South America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Type (2017-2022)
  • 9.3 South America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Application (2017-2022)
  • 9.4 South America T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Country (2017-2022)
    • 9.4.1 Brazil

10 MIDDLE EAST & AFRICA

  • 10.1 Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size (2017-2028)
  • 10.2 Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Type (2017-2022)
  • 10.3 Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Application (2017-2022)
  • 10.4 Middle East & Africa T-Cell & NK-Cell Engaging Bispecific Antibodies Market Size by Country (2017-2022)
    • 10.4.1 Middle East
    • 10.4.2 Africa

11 KEY PLAYERS PROFILES

  • 11.1 Amgen
    • 11.1.1 Amgen Company Details
    • 11.1.2 Amgen Business Overview
    • 11.1.3 Amgen T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction
    • 11.1.4 Amgen Revenue in T-Cell & NK-Cell Engaging Bispecific Antibodies Business (2017-2022)
    • 11.1.5 Amgen Recent Development
  • 11.2 Immunocore
    • 11.2.1 Immunocore Company Details
    • 11.2.2 Immunocore Business Overview
    • 11.2.3 Immunocore T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction
    • 11.2.4 Immunocore Revenue in T-Cell & NK-Cell Engaging Bispecific Antibodies Business (2017-2022)
    • 11.2.5 Immunocore Recent Development
  • 11.3 Johnson & Johnson
    • 11.3.1 Johnson & Johnson Company Details
    • 11.3.2 Johnson & Johnson Business Overview
    • 11.3.3 Johnson & Johnson T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction
    • 11.3.4 Johnson & Johnson Recent Development
  • 11.4 Roche
    • 11.4.1 Roche Company Details
    • 11.4.2 Roche Business Overview
    • 11.4.3 Roche T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction
    • 11.4.4 Roche Recent Development
  • 11.5 Pfizer
    • 11.5.1 Pfizer Company Details
    • 11.5.2 Pfizer Business Overview
    • 11.5.3 Pfizer T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction
    • 11.5.4 Pfizer Recent Development
  • 11.6 AbbVie
    • 11.6.1 AbbVie Company Details
    • 11.6.2 AbbVie Business Overview
    • 11.6.3 AbbVie T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction
    • 11.6.4 AbbVie Recent Development
  • 11.7 MacroGenics
    • 11.7.1 MacroGenics Company Details
    • 11.7.2 MacroGenics Business Overview
    • 11.7.3 MacroGenics T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction
    • 11.7.4 MacroGenics Recent Development
  • 11.8 Regeneron
    • 11.8.1 Regeneron Company Details
    • 11.8.2 Regeneron Business Overview
    • 11.8.3 Regeneron T-Cell & NK-Cell Engaging Bispecific Antibodies Introduction
    • 11.8.4 Regeneron Recent Development
  • 11.9 Astellas Pharma
    • 11.9.1 Astellas Pharma Company Details
    • 11.9.2 Astellas Pharma Business Overview
    • 11.9.3 Astellas Pharma Recent Development
  • 11.10 GEMoaB Monoclonals
    • 11.10.1 GEMoaB Monoclonals Company Details
    • 11.10.2 GEMoaB Monoclonals Business Overview
    • 11.10.3 GEMoaB Monoclonals Recent Development
  • 11.11 Molecular Partners
    • 11.11.1 Molecular Partners Company Details
    • 11.11.2 Molecular Partners Business Overview
    • 11.11.3 Molecular Partners Recent Development
  • 11.12 AstraZeneca
    • 11.12.1 AstraZeneca Company Details
    • 11.12.2 AstraZeneca Business Overview
    • 11.12.3 AstraZeneca Recent Development
  • 11.13 Merck
    • 11.13.1 Merck Company Details
    • 11.13.2 Merck Business Overview
    • 11.13.3 Merck Recent Development
  • 11.14 Eli Lilly
    • 11.14.1 Eli Lilly Company Details
    • 11.14.2 Eli Lilly Business Overview
    • 11.14.3 Eli Lilly Recent Development
  • 11.15 IGM Biosciences
    • 11.15.1 IGM Biosciences Company Details
    • 11.15.2 IGM Biosciences Business Overview
    • 11.15.3 IGM Biosciences Recent Development
  • 11.16 Novartis
    • 11.16.1 Novartis Company Details
    • 11.16.2 Novartis Business Overview
    • 11.16.3 Novartis Recent Development
  • 11.17 CytomX Therapeutics
    • 11.17.1 CytomX Therapeutics Company Details
    • 11.17.2 CytomX Therapeutics Business Overview
    • 11.17.3 CytomX Therapeutics Recent Development
  • 11.18 Lava Therapeutics
    • 11.18.1 Lava Therapeutics Company Details
    • 11.18.2 Lava Therapeutics Business Overview
    • 11.18.3 Lava Therapeutics Recent Development
  • 11.19 Takeda
    • 11.19.1 Takeda Company Details
    • 11.19.2 Takeda Business Overview
    • 11.19.3 Takeda Recent Development

12 ANALYST'S VIEWPOINTS/CONCLUSIONS

13 APPENDIX

  • 13.1 Research Methodology
    • 13.1.1 Methodology/Research Approach
    • 13.1.2 Data Source
  • 13.2 Disclaimer
  • 13.3 Author Details 95